What is the share price of Nectar Lifesciences Ltd (NECLIFE) today?
The share price of NECLIFE as on 5th December 2025 is ₹20.95. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nectar Lifesciences Ltd (NECLIFE) share?
The past returns of Nectar Lifesciences Ltd (NECLIFE) share are- Past 1 week: 18.34%
- Past 1 month: 22.82%
- Past 3 months: 42.84%
- Past 6 months: -14.04%
- Past 1 year: -38.77%
- Past 3 years: -1.23%
- Past 5 years: 5.23%
What are the peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE)?
The peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE) include:What is the market cap of Nectar Lifesciences Ltd (NECLIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nectar Lifesciences Ltd (NECLIFE) is ₹469.60 Cr as of 5th December 2025.What is the 52 week high and low of Nectar Lifesciences Ltd (NECLIFE) share?
The 52-week high of Nectar Lifesciences Ltd (NECLIFE) is ₹44.41 and the 52-week low is ₹13.05.What is the PE and PB ratio of Nectar Lifesciences Ltd (NECLIFE) stock?
The P/E (price-to-earnings) ratio of Nectar Lifesciences Ltd (NECLIFE) is -4.13. The P/B (price-to-book) ratio is 0.49.Which sector does Nectar Lifesciences Ltd (NECLIFE) belong to?
Nectar Lifesciences Ltd (NECLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Nectar Lifesciences Ltd (NECLIFE) shares?
You can directly buy Nectar Lifesciences Ltd (NECLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nectar Lifesciences Ltd
NECLIFE Share Price
20.950.05% (+0.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
NECLIFE Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
NECLIFE Performance & Key Metrics
NECLIFE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -1.30 | 0.49 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
NECLIFE Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
NECLIFE Company Profile
Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.
SUNPHARMA
PE Ratio
39.92
39.92
1Y Return
1.01%
1.01%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.21
67.21
1Y Return
13.21%
13.21%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.34%
1.34%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.81
18.81
1Y Return
5.10%
5.10%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.12
29.12
1Y Return
0.46%
0.46%
Buy Reco %
72.22
72.22
NECLIFE Forecast
NECLIFE Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
NECLIFE
NECLIFE
Income
Balance Sheet
Cash Flow
Annual Normal View
NECLIFE Income Statement
NECLIFE Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,666.37 | 1,882.29 | 2,788.91 | 2,370.70 | 1,547.08 | 1,680.15 | 1,566.85 | 1,698.66 | 1,674.96 | 897.63 | ||||||||||
Raw Materials | 1,145.85 | 1,417.32 | 2,268.13 | 1,862.83 | 1,052.82 | 1,207.32 | 1,200.84 | 1,242.45 | 1,250.72 | 1,245.62 | ||||||||||
| Power & Fuel Cost | 75.44 | 91.85 | 103.47 | 92.72 | 84.63 | 101.41 | 127.39 | 129.52 | 104.16 | |||||||||||
| Employee Cost | 75.54 | 74.65 | 76.54 | 78.19 | 70.59 | 71.91 | 75.14 | 81.71 | 93.61 | |||||||||||
| Selling & Administrative Expenses | 59.98 | 52.23 | 67.99 | 67.01 | 72.04 | 66.86 | 62.64 | 61.39 | 71.17 | |||||||||||
| Operating & Other expenses | 62.48 | 4.06 | 2.56 | 45.89 | 179.49 | 62.79 | 4.66 | 17.46 | 179.87 | |||||||||||
EBITDA | 247.08 | 242.18 | 270.22 | 224.06 | 87.51 | 169.86 | 96.18 | 166.13 | -24.57 | -347.99 | ||||||||||
| Depreciation/Amortization | 62.25 | 64.31 | 63.26 | 60.77 | 60.25 | 56.97 | 59.12 | 60.72 | 62.39 | 32.11 | ||||||||||
| PBIT | 184.83 | 177.87 | 206.96 | 163.29 | 27.26 | 112.89 | 37.06 | 105.41 | -86.96 | -380.10 | ||||||||||
| Interest & Other Items | 117.41 | 115.20 | 148.14 | 125.83 | 112.04 | 78.81 | 79.49 | 87.14 | 74.58 | 34.79 | ||||||||||
| PBT | 67.42 | 62.67 | 58.82 | 37.46 | -84.78 | 34.08 | -42.43 | 18.27 | -161.54 | -414.89 | ||||||||||
| Taxes & Other Items | 12.08 | 10.41 | 11.22 | 5.68 | -11.50 | 9.03 | -18.24 | 13.28 | -47.85 | -53.42 | ||||||||||
| Net Income | 55.34 | 52.26 | 47.60 | 31.78 | -73.28 | 25.05 | -24.19 | 4.99 | -113.69 | -361.47 | ||||||||||
| EPS | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -16.12 | ||||||||||
| DPS | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.02 | 0.02 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NECLIFE Company Updates
NECLIFE Stock Peers
NECLIFE Past Performance & Peer Comparison
NECLIFE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nectar Lifesciences Ltd | -4.13 | 0.49 | — |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
NECLIFE Stock Price Comparison
Compare NECLIFE with any stock or ETFCompare NECLIFE with any stock or ETF
NECLIFE
NECLIFE Holdings
NECLIFE Shareholdings
NECLIFE Promoter Holdings Trend
NECLIFE Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
NECLIFE Institutional Holdings Trend
NECLIFE Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 2.30%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
NECLIFE Shareholding Pattern
NECLIFE Shareholding Pattern
NECLIFE Shareholding History
NECLIFE Shareholding History
Foreign Institutions
Mutual Funds Invested in NECLIFE
Mutual Funds Invested in NECLIFE
No mutual funds holding trends are available
Top 1 Mutual Funds holding Nectar Lifesciences Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0006% | Percentage of the fund’s portfolio invested in the stock 0.01% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 120/124 (0) |
Compare 3-month MF holding change on Screener
smallcases containing NECLIFE stock
smallcases containing NECLIFE stock
Looks like this stock is not in any smallcase yet.
NECLIFE Events
NECLIFE Events
NECLIFE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NECLIFE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
NECLIFE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
NECLIFE has not given any dividends in last 5 years
NECLIFE Upcoming Dividends
NECLIFE Upcoming Dividends
No upcoming dividends are available
NECLIFE Past Dividends
NECLIFE Past Dividends
Cash Dividend
Ex DateEx DateSep 11, 2020
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 11, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 19, 2018
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2018
Cash Dividend
Ex DateEx DateSep 20, 2017
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 20, 2017
Cash Dividend
Ex DateEx DateSep 22, 2016
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2016
NECLIFE Stock News & Opinions
NECLIFE Stock News & Opinions
Articles & Videos
Corporate
Nectar Lifescience to conduct board meeting
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 3 December 2025.Powered by Capital Market - Live
6 days agoCapital Market - Live
Earnings
Nectar Lifescience reports consolidated net loss of Rs 176.01 crore in the September 2025 quarter
Net loss of Nectar Lifescience reported to Rs 176.01 crore in the quarter ended September 2025 as against net profit of Rs 5.60 crore during the previous quarter ended September 2024. Sales declined 12.74% to Rs 5.00 crore in the quarter ended September 2025 as against Rs 5.73 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales5.005.73 -13 OPM %-6.60-10.30 - PBDT-0.300.10 PL PBT-0.50-0.35 -43 NP-176.015.60 PL Powered by Capital Market - Live
2 weeks agoCapital Market - Live
Corporate
Nectar Lifescience announces board meeting date
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Nectar Lifescience to convene AGM
Nectar Lifescience announced that the 30th Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Nectar Lifescience reports consolidated net loss of Rs 63.23 crore in the June 2025 quarter
Net loss of Nectar Lifescience reported to Rs 63.23 crore in the quarter ended June 2025 as against net profit of Rs 2.97 crore during the previous quarter ended June 2024. Sales declined 21.79% to Rs 280.67 crore in the quarter ended June 2025 as against Rs 358.85 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales280.67358.85 -22 OPM %-22.0511.09 - PBDT-80.2420.38 PL PBT-96.754.92 PL NP-63.232.97 PL Powered by Capital Market - Live
3 months agoCapital Market - Live
Earnings
Nectar Lifescience reports standalone net loss of Rs 63.23 crore in the June 2025 quarter
Net loss of Nectar Lifescience reported to Rs 63.23 crore in the quarter ended June 2025 as against net profit of Rs 2.97 crore during the previous quarter ended June 2024. Sales declined 21.79% to Rs 280.67 crore in the quarter ended June 2025 as against Rs 358.85 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales280.67358.85 -22 OPM %-22.0511.09 - PBDT-80.2320.38 PL PBT-96.754.92 PL NP-63.232.97 PL Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Nectar Lifescience schedules board meeting
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 August 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Nectar Lifescience to hold board meeting
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 23 July 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Spotlight
Nectar Lifescience Ltd leads losers in 'B' group
Lokesh Machines Ltd, Rhetan TMT Ltd, Vibhor Steel Tubes Ltd and Dreamfolks Services Ltd are among the other losers in the BSE's 'B' group today, 09 July 2025.Nectar Lifescience Ltd tumbled 9.93% to Rs 16.69 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 28.52 lakh shares were traded on the counter so far as against the average daily volumes of 2.2 lakh shares in the past one month.Lokesh Machines Ltd crashed 7.85% to Rs 218.85. The stock was the second biggest loser in 'B' group.On the BSE, 42757 shares were traded on the counter so far as against the average daily volumes of 12459 shares in the past one month.Rhetan TMT Ltd lost 7.75% to Rs 17.49. The stock was the third biggest loser in 'B' group.On the BSE, 21.83 lakh shares were traded on the counter so far as against the average daily volumes of 6.83 lakh shares in the past one month.Vibhor Steel Tubes Ltd slipped 5.35% to Rs 182.3. The stock was the fourth biggest loser in 'B' group.On the BSE, 6454 shares were traded on the counter so far as against the average daily volumes of 9926 shares in the past one month.Dreamfolks Services Ltd dropped 5.29% to Rs 167.55. The stock was the fifth biggest loser in 'B' group.On the BSE, 3.18 lakh shares were traded on the counter so far as against the average daily volumes of 1.15 lakh shares in the past one month.Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Nectar Lifescience EGM scheduled
Nectar Lifescience announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 4 August 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -6.71%, vs industry avg of 10.03%
Over the last 5 years, market share decreased from 0.94% to 0.4%